In Defense of USP Singlet Testing

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-02-02-2005, Volume 29, Issue 2

The United States Pharmacopeia should not change its philosophical position on singlet testing.

Related Content:

AnalyticsProcess ValidationQuality SystemsDevelopmentCompendial CompliancePharmaceutical Technology-02-02-2005
Reliance-Based Waivers Become the Predominant Trend in In-Country Testing of Pharmaceutical Products
Poseida Therapeutics and Astellas to Develop Novel Allogeneic Cell Therapies
Using Taste-Masking and Appearance to Address Patient-Specific Needs